# Ascentage Pharma Group International: overview

AAPG · Nasdaq · CIK 2023311 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/aapg.md) · [Financials](/companies/aapg/financials.md) · [Filings](/companies/aapg/filings.md) · [Insiders](/companies/aapg/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

Not reported.

## Last five fiscal years

| Line item | Unit | FY2024 (2024-12-31) |
| --- | --- | ---: |
| Revenue | $m | [134](/filings/0001213900-25-032599.md) |
| Gross margin | % | [97.0%](/filings/0001213900-25-032599.md) |
| Operating margin | % | not reported |
| Net margin | % | [(41.3%)](/filings/0001213900-25-032599.md) |
| Diluted EPS | $ per share | [(0.18)](/filings/0001213900-25-032599.md) |
| Free cash flow | $m | [(18.6)](/filings/0001213900-25-032599.md) |

- Revenue. XBRL Revenue: ifrs-full:Revenue.
- Gross margin (gross profit / revenue). XBRL Gross profit: ifrs-full:GrossProfit; Revenue: ifrs-full:Revenue.
- Operating margin (operating income / revenue). XBRL Revenue: ifrs-full:Revenue.
- Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent; Revenue: ifrs-full:Revenue.
- Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/aapg/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Point72 Asset Management, L.P.](/funds/1603466.md) | 2026-06-30 | $243.0k | 13,841 |  | Reduced −2,215 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $16.1k | 919 |  | Added +421 |
| [WELLS FARGO & COMPANY/MN](/funds/72971.md) | 2026-06-30 | $3.5k | 200 |  | New +200 |
| [EverSource Wealth Advisors, LLC](/funds/1710537.md) | 2026-06-30 | $421 | 24 |  | Unchanged |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $263 | 15 |  | Reduced −109 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $105 | 6 |  | New +6 |
| [Caitong International Asset Management Co., Ltd](/funds/1963355.md) | 2026-06-30 | $18 | 1 |  | New +1 |
| [ROYAL BANK OF CANADA](/funds/1000275.md) | 2026-06-30 | $0 | 6 |  | Unchanged |

## Recent filings

[All 132 filings](/companies/aapg/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-28 | 09:10 ET | [6-K](/filings/0001213900-26-113124.md) | Report of a foreign private issuer, period 2026-10-28 | 0001213900-26-113124 |
| 2026-10-22 | 16:44 ET | [6-K](/filings/0001213900-26-111727.md) | Report of a foreign private issuer, period 2026-10-22 | 0001213900-26-111727 |
| 2026-10-21 | 16:55 ET | [6-K](/filings/0001213900-26-111393.md) | Report of a foreign private issuer, period 2026-10-21 | 0001213900-26-111393 |
| 2026-10-15 | 09:26 ET | [6-K](/filings/0001213900-26-109623.md) | Report of a foreign private issuer, period 2026-10-15 | 0001213900-26-109623 |
| 2026-09-29 | 18:14 ET | [6-K](/filings/0001213900-26-104196.md) | Report of a foreign private issuer, period 2026-09-28 | 0001213900-26-104196 |
| 2026-09-17 | 08:30 ET | [6-K](/filings/0001213900-26-100763.md) | Report of a foreign private issuer, period 2026-09-17 | 0001213900-26-100763 |
| 2026-08-20 | 08:13 ET | [6-K](/filings/0001213900-26-091901.md) | Report of a foreign private issuer, period 2026-08-20 | 0001213900-26-091901 |
| 2026-08-13 | 09:29 ET | [6-K](/filings/0001213900-26-088773.md) | Report of a foreign private issuer, period 2026-08-13 | 0001213900-26-088773 |
| 2026-08-05 | 09:16 ET | [6-K](/filings/0001213900-26-085424.md) | Report of a foreign private issuer, period 2026-08-05 | 0001213900-26-085424 |
| 2026-08-03 | 07:30 ET | [6-K](/filings/0001213900-26-084247.md) | Report of a foreign private issuer, period 2026-08-03 | 0001213900-26-084247 |

## Latest annual report

[Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-049412.md), filed Apr 29, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 2023311
- Tickers: AAPG
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: E9
- Filer category: Non-accelerated filer<br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 28, 2026, 09:12 ET. No prices; not investment advice.